Skip to main content

XTL Biopharmaceuticals Ltd.

corporate_fare Company Profile

XTL Biopharmaceuticals Ltd.

XTLB·NASDAQ·Life Sciences·CIK 0001023549

XTL BIOPHARMACEUTICALS LTD is an intellectual property-based company focused on developing, managing, and commercializing intellectual property. The company operates in the biotech sector through its subsidiary, Psyga Bio, and in the biopharmaceutical industry. In the biopharmaceutical industry, XTL BIOPHARMACEUTICALS LTD holds a license from Yeda Research and Development Company Ltd. for hCDR1, a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). In March 2025, XTL BIOPHARMACEUTICALS LTD entered into an Exclusive Sublicense Agreement with Biossil Inc., a Canadian company. Under this agreement, XTL BIOPHARMACEUTICALS LTD granted Biossil a royalty-free, exclusive, worldwide perpetual sublicense, with multi-tier sublicensing rights, for its synthetic peptide, hCDR1. This sublicense includes related patent applications, provisional applications, resulting patents, and all know-how, including clinical and pre-clinical data related to the product called Edratide, as well as trademarks, trade names, logos, and labeling necessary for its research, development, manufacture, and commercialization. Yeda was informed and agreed to this agreement. In April 2026, XTL BIOPHARMACEUTICALS LTD acquired Psyga Bio Ltd., an Israeli company. Psyga Bio is an advanced biotechnology company researching, developing, and commercializing proprietary products from psychedelic and functional mushrooms, including therapeutic candidates, microdosing solutions, and wellness formulations. Psyga Bio operates a licensed, GMP-ready pharmaceutical manufacturing facility for the cultivation, extraction, isolation, formulation, and production of pharmaceutical-grade botanical and synthetic psilocybin, Ibogaine, and other psychedelic active pharmaceutical ingredients (APIs), adhering to international pharmaceutical manufacturing standards.

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for XTLB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for XTLB spans 6-K, 20-F.

Recent high-impact activity:

  • XTL Sets Dec 28 Vote on $1M Related-Party Placement, New CEO and Psyga Name Change
  • XTL Reports H1 2026 Loss of $899K; Discloses Psyga Deal, $1.5M Placement and New Derivative Claim
  • Derivative Claim Targets XTL Biopharmaceuticals Over Failed Social Proxy Acquisition
  • XTL Biopharmaceuticals Regains Full Nasdaq Compliance, Resolving Multiple Delisting Threats
  • XTL Biopharmaceuticals Files Delayed 20-F, Reveals Going Concern Warning, Negative Equity, and Major Business Pivot to Psychedelic Therapeutics Amidst Nasdaq Delisting Risk

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$6.97M
Diluted EPS
-$0.01
Op. Cash Flow
-$1.02M
Operating Income
-$1.69M
Cash & Equivalents
$76K
Debt / Equity
0.00×
Shares Outstanding
946.24M sh
Source: 20-F · filed 2026-06-30 · accession 0001213900-26-073831

Short Interest & Short Volume

1.05 days to cover

FINRA reported short interest of 4,271 shares in XTLB as of the October 30, 2026 settlement, a 2.2% increase from the prior period — about 1.1 days to cover at its recent average daily volume. On November 20, 2026, 0.2% of XTLB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,271 shares as of October 30, 2026
Change vs prior period▲ 2.2%
Days to cover1.05 at avg daily volume of 4,082
Daily short volume (FINRA facilities)0.2% of 1,203 shares on November 20, 2026
5-day average short volume28.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for XTLB, detected from its recent SEC filings · based on capital-structure filings through 2026-11-20.

Related-Party Placement Up to $1M · Warrant Reset Adds Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

XTLB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with X →
$1.37 -7.43% today
52-week range · as of 2026-11-20 $1.37 – $5.64
Market cap
$6.83M
Volume
1.8K (0.3× avg)
3-mo avg 5.7K
Live data · 2026-11-22 00:03 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed XTLB - Latest Insights

XTLB
Nov 20, 2026, 4:06 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.37
Real-time Price: $1.37 info
Change: $0 (0%) info
Market Cap: $6.831M info
XTLB
Nov 18, 2026, 4:00 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.54
Real-time Price: $1.37 info
Change: -$0.170 (-11%) info
Market Cap: $6.831M info
XTLB
Aug 05, 2026, 4:21 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.85
Real-time Price: $1.37 info
Change: -$1.48 (-52%) info
Market Cap: $6.831M info
XTLB
Jul 21, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.92
Real-time Price: $1.37 info
Change: -$1.55 (-53%) info
Market Cap: $6.831M info
XTLB
Jun 30, 2026, 5:24 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $3.96
Real-time Price: $1.37 info
Change: -$2.59 (-65%) info
Market Cap: $6.831M info
XTLB
Jun 30, 2026, 5:16 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.85
Real-time Price: $1.37 info
Change: -$1.48 (-52%) info
Market Cap: $6.831M info
XTLB
Jun 29, 2026, 4:39 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.36
Real-time Price: $1.37 info
Change: -$0.990 (-42%) info
Market Cap: $6.831M info
XTLB
Jun 22, 2026, 7:23 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.48
Real-time Price: $1.37 info
Change: -$1.11 (-45%) info
Market Cap: $6.831M info
XTLB
May 22, 2026, 4:11 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.69
Real-time Price: $1.37 info
Change: -$1.32 (-49%) info
Market Cap: $6.831M info
XTLB
May 15, 2026, 5:09 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.61
Real-time Price: $1.37 info
Change: -$1.24 (-48%) info
Market Cap: $6.831M info
XTLB
May 07, 2026, 8:10 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.64
Real-time Price: $1.37 info
Change: -$2.27 (-62%) info
Market Cap: $6.831M info
XTLB
Apr 29, 2026, 9:07 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.60
Real-time Price: $1.37 info
Change: -$2.23 (-62%) info
Market Cap: $6.831M info
XTLB
Mar 20, 2026, 4:11 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.590
Real-time Price: $1.37 info
Change: Reverse Stock Split info
Market Cap: $6.831M info
XTLB
Mar 10, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.633
Real-time Price: $1.37 info
Change: Reverse Stock Split info
Market Cap: $6.831M info
XTLB
Feb 27, 2026, 4:34 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.700
Real-time Price: $1.37 info
Change: Reverse Stock Split info
Market Cap: $6.831M info
XTLB
Feb 24, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.7998
Real-time Price: $1.37 info
Change: Reverse Stock Split info
Market Cap: $6.831M info
XTLB
Feb 23, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.8299
Real-time Price: $1.37 info
Change: Reverse Stock Split info
Market Cap: $6.831M info
XTLB
Feb 17, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.840
Real-time Price: $1.37 info
Change: Reverse Stock Split info
Market Cap: $6.831M info
XTLB
Jan 28, 2026, 8:58 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.850
Real-time Price: $1.37 info
Change: Reverse Stock Split info
Market Cap: $6.831M info
XTLB
Jan 23, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.08
Real-time Price: $1.37 info
Change: Reverse Stock Split info
Market Cap: $6.831M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets